Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-PV-01 Vaccine with Pembrolizumab and Chemo in Lung Cancer
NCT03166254Phase 1Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2019
- Primary completion
- Jun 2022
- Modality
- Peptides, Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label trial of NeoVax in squamous cell carcinoma of the lung (SCCL) and small cell lung cancer (SCLC) (2 cohorts), sponsored by Washington University School of Medicine. Primary endpoint: Number of participants who experience a serious adverse event. Planned start Apr 2019; status: withdrawn.
02
Drugs
NeoVax
03
Conditions
squamous cell carcinoma of the lung (SCCL)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03166254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03166254.